Modulators of Caspase-6

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a pharmaceutical composition that contains arylpropynamide derivatives as specific inhibitors of caspase-6, an enzyme implicated in the development of neurodegenerative diseases such as Huntington's disease and Alzheimer's disease. By inhibiting caspase-6, these compounds aim to prevent or reduce the abnormal cleavage of key neuronal proteins, thereby protecting neurons from damage and slowing disease progression. The drugs can be administered by various routes, including orally, intravenously, or even directly into the brain or spinal fluid, and may be used alone or in combination with standard neurological therapies.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of neurodegenerative diseases such as Huntington's disease and Alzheimer's disease.
• Prevention or slowing of cognitive decline in patients with mild cognitive impairment or dementia.
• Protecting neurons from apoptosis (programmed cell death) in acute neurological injuries, such as stroke or traumatic brain injury.
• Adjunct therapy alongside standard medications for neurodegeneration (e.g., L-DOPA, memantine).
• Potential use as a research tool for studying the role of caspase-6 in neuronal degeneration in vitro and in vivo.

BenefitsContent extracted from patent full text and abstract with AI.

• Targets a specific molecular mechanism (caspase-6 inhibition) strongly linked to neurodegeneration, potentially offering greater efficacy and fewer side effects compared to non-specific treatments.
• May be administered via multiple routes (oral, injection, infusion, intranasal), providing flexibility in clinical application.
• Demonstrated ability to improve neuronal survival during excitotoxic or degenerative conditions as shown in cell and animal models.
• Potential for use in combination with existing neuroprotective drugs, enhancing overall therapeutic effectiveness.
• Could be administered for both symptomatic relief and prevention in at-risk individuals before the onset of clinical symptoms.
• Advances the field by introducing non-peptide, small molecule caspase-6 inhibitors, which may have improved drug-like properties and blood-brain barrier penetration over previous inhibitors.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The current application relates to a pharmaceutical composition for the treatment or amelioration of a neurological disease, wherein the composition comprises a therapeutically effective amount of a caspase-6 inhibitor which is an arylpropynamide derivative. The composition can be formulated for oral or topical administration, subcutaneous, intravenous, or intramuscular injection, infusion, inhalation, or intrthecal injection.